202 related articles for article (PubMed ID: 30036258)
21.
Fendler WP; Eiber M; Beheshti M; Bomanji J; Ceci F; Cho S; Giesel F; Haberkorn U; Hope TA; Kopka K; Krause BJ; Mottaghy FM; Schöder H; Sunderland J; Wan S; Wester HJ; Fanti S; Herrmann K
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):1014-1024. PubMed ID: 28283702
[TBL] [Abstract][Full Text] [Related]
22. 68Ga Prostate-Specific Membrane Antigen Uptake in Renal Cell Cancer Lymph Node Metastases.
Einspieler I; Tauber R; Maurer T; Schwaiger M; Eiber M
Clin Nucl Med; 2016 May; 41(5):e261-2. PubMed ID: 26859205
[TBL] [Abstract][Full Text] [Related]
23. Incidentally Detected 18F-PSMA Uptake in Glomus Jugulare.
Zade A; Trivedi C; Ingule A; Jha S; Agrwal A
Clin Nucl Med; 2020 Aug; 45(8):e360-e362. PubMed ID: 32520502
[TBL] [Abstract][Full Text] [Related]
24. 68Ga-Labeled Anti-Prostate-Specific Membrane Antigen Peptide as Marker for Androgen Deprivation Therapy Response in Prostate Cancer.
Schlenkhoff CD; Gaertner F; Essler M; Hauser S; Ahmadzadehfar H
Clin Nucl Med; 2016 May; 41(5):423-5. PubMed ID: 26859213
[TBL] [Abstract][Full Text] [Related]
25. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
[TBL] [Abstract][Full Text] [Related]
26.
Henkenberens C; VON Klot CA; Ross TL; Bengel FM; Wester HJ; Katja H; Christiansen H; Derlin T
Anticancer Res; 2017 Mar; 37(3):1273-1279. PubMed ID: 28314292
[TBL] [Abstract][Full Text] [Related]
27. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
[TBL] [Abstract][Full Text] [Related]
28. 68Ga-PSMA PET/CT Uptake in the Ureter Caused by Ligand Expression in Urothelial Cancer.
Zacho HD; Pedersen SH; Petersen A; Petersen LJ
Clin Nucl Med; 2020 Jan; 45(1):e43-e45. PubMed ID: 31306199
[TBL] [Abstract][Full Text] [Related]
29. PSMA Ligands for PET Imaging of Prostate Cancer.
Schwarzenboeck SM; Rauscher I; Bluemel C; Fendler WP; Rowe SP; Pomper MG; Afshar-Oromieh A; Herrmann K; Eiber M
J Nucl Med; 2017 Oct; 58(10):1545-1552. PubMed ID: 28687599
[TBL] [Abstract][Full Text] [Related]
30. PSMA PET and Radionuclide Therapy in Prostate Cancer.
Bouchelouche K; Turkbey B; Choyke PL
Semin Nucl Med; 2016 Nov; 46(6):522-535. PubMed ID: 27825432
[TBL] [Abstract][Full Text] [Related]
31.
Herlemann A; Wenter V; Kretschmer A; Thierfelder KM; Bartenstein P; Faber C; Gildehaus FJ; Stief CG; Gratzke C; Fendler WP
Eur Urol; 2016 Oct; 70(4):553-557. PubMed ID: 26810345
[TBL] [Abstract][Full Text] [Related]
32. Utility of
Siva S; Callahan J; Pryor D; Martin J; Lawrentschuk N; Hofman MS
J Med Imaging Radiat Oncol; 2017 Jun; 61(3):372-378. PubMed ID: 28116853
[TBL] [Abstract][Full Text] [Related]
33. The
Scarpa L; Buxbaum S; Kendler D; Fink K; Bektic J; Gruber L; Decristoforo C; Uprimny C; Lukas P; Horninger W; Virgolini I
Eur J Nucl Med Mol Imaging; 2017 May; 44(5):788-800. PubMed ID: 28083690
[TBL] [Abstract][Full Text] [Related]
34. Effective Prostate-Specific Membrane Antigen-Based 18F-DCFPyL-Guided Cryoablation of a Single Positive Site in a Patient Believed to Be More Metastatic on 11C-Choline PET/CT.
Cornelis FH; Durack JC; Morris MJ; Scher HI; Solomon SB
Clin Nucl Med; 2017 Dec; 42(12):e516-e518. PubMed ID: 29099733
[TBL] [Abstract][Full Text] [Related]
35. Current application and future perspectives of prostate specific membrane antigen PET imaging in prostate cancer.
Ceci F; Castellucci P; Fanti S
Q J Nucl Med Mol Imaging; 2019 Mar; 63(1):7-18. PubMed ID: 29521482
[TBL] [Abstract][Full Text] [Related]
36. A Rare Case of Omentum Invasive Prostate Cancer: Staging With PSMA PET/CT Imaging and Response to Systemic Therapy.
Ladwa R; Gustafson S; McCaffrey E; Miles K; O'Byrne K
Clin Nucl Med; 2017 Jun; 42(6):e311-e312. PubMed ID: 28240670
[TBL] [Abstract][Full Text] [Related]
37. [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH.
Afshar-Oromieh A; Haberkorn U; Eder M; Eisenhut M; Zechmann CM
Eur J Nucl Med Mol Imaging; 2012 Jun; 39(6):1085-6. PubMed ID: 22310854
[No Abstract] [Full Text] [Related]
38. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U
Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446
[TBL] [Abstract][Full Text] [Related]
39. 68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT.
Bluemel C; Krebs M; Polat B; Linke F; Eiber M; Samnick S; Lapa C; Lassmann M; Riedmiller H; Czernin J; Rubello D; Bley T; Kropf S; Wester HJ; Buck AK; Herrmann K
Clin Nucl Med; 2016 Jul; 41(7):515-21. PubMed ID: 26975008
[TBL] [Abstract][Full Text] [Related]
40. Prostate-Specific Membrane Antigen-Avid Neurofibroma Mimicking Cutaneous Metastasis in Metastatic Castration-Resistant Prostate Cancer on 18 F-PSMA-1007 PET/CT.
Aggarwal P; Ambalavanan N; Sood A; Gupta K; Dahiya D; Mittal BR
Clin Nucl Med; 2024 Jun; 49(6):e286-e287. PubMed ID: 38598513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]